- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01812382
Retapamulin Microdialysis Feasibility Study
A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GlaxoSmithKline (GSK) Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. Subjects with clinically significant lab values outside the normal range should always be excluded from enrollment.
- The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and is likely to complete the study as planned. Subject is willing to provide informed consent.
- Does not use medications containing Retapamulin while participating in the study.
- Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- Body Mass Index within the range 18.5 to 32 kilogram/ meter^2 (inclusive).
- The following normal ranges for blood pressure and heart rate are given as a guide: Systolic blood pressure 90 to 140 milimeter of Mercury (mmHg), Diastolic blood pressure 60 to 90 mmHg, and Heart rate 45 to 100 beats per minute (bpm). The investigator may interpret screening vital sign data based on the subject's age, physical state and level of fitness. Subjects with vital sign readings marginally outside the normal range may be included in the study if in the investigator's opinion these values are not clinically significant and will not present a safety risk or affect study assessments.
- A female subject is eligible to participate if she is of non-childbearing potential (defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone > 40 milli international unit/mililiter (mL) and estradiol < 40 picogram/ml [<147 picomoles/Liter] is confirmatory]. Females on hormone replacement therapy and whose menopausal status is in doubt will be required to use one of the contraception methods) or Child-bearing potential and agrees to use one of the contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until study completion (i.e. follow-up phone call). Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until study completion (i.e. follow-up phone call).
- Alanine aminotransferase, alkaline phosphatase and bilirubin <= 1.5x Upper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
- QT interval corrected for Heart rate (QTc), QTcB (Bazett's formula) or QTcF (Fridericia's formula) < 450 millisecond (msec); or QTc < 480 msec in subjects with Bundle Branch Block.
- Does not currently smoke cigarettes or tobacco and has not smoked within the past 12 months prior to the study.
- Does not consume alcohol 72 hours prior to the start of and during the study
Exclusion Criteria:
- Unwillingness or inability to follow the procedures outlined in the protocol
- Subject is mentally or legally incapacitated.
- History of current significant medical illness including cardiovascular thrombotic events, myocardial infarction, stroke or other cardiac disease, hypertension, peptic ulcer disease or gastrointestinal bleeding, skin disorders, hematological disease, bronchospastic respiratory disease, asthma, diabetes mellitus, renal or hepatic insufficiency, or any other illness that the investigator deems clinically significant for exclusion of the subject from the study.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of skin conditions including atopic dermatitis, dry skin, or ichtyosis vulgaris.
- Surgical history within 3 months prior to the start of the study.
- Clinically significant acute illness 7 days prior to study start.
- Excessive hair, tattooing, scar tissue, or other tissue damage at the application site that could affect drug recovery or patient safety.
- Use of topical moisturizers (does not include facial moisturizers) 48 hours before the start of and during the study.
- Strenuous exercise 48 hours before the start of and during the study.
- Unable to refrain from the use of non-prescription drugs, including non- steroidal ant-inflammatory drugs (NSAIDS), vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360mL) of beer; 5 ounces (150mL) of wine; or 1.5 ounce (45mL) of 80 proof distilled spirits.
- A positive pre-study drug/alcohol screen.
- Pregnant females as determined by positive serum human chorionic gonadotropin (hCG) at screening or urine hCG test prior to dosing.
- Lactating females.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Employees of the investigator or study center, with direct involvement in the proposed study or similar studies including family members of the employees or the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Microdialysis arm
Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device.
All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
|
After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes.
The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retapamulin concentrations in the dialysate samples
Time Frame: Single day
|
Retapamulin concentrations in the dialysate samples will be collected to calculate the length of time needed until disappearance of the drug in the dialysate (washout) and the percentage of drug recovered following perfusion of Retapamulin solution by microdialysis to the thigh of healthy volunteers.
Microdialysis is a minimally-invasive sampling technique that is used for continuous measurement of free, unbound analyte concentrations in the extracellular fluid of virtually any tissue
|
Single day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by number of participants with Adverse Events (AEs)
Time Frame: Up to 4 days
|
Adverse event collection and recording will begin with first dose and continue until the final follow-up visit
|
Up to 4 days
|
Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by Laboratory parameters
Time Frame: Single day
|
Laboratory parameters include: Hematology, Clinical Chemistry and additional parameters
|
Single day
|
Safety and tolerability of the microdialysis technique with perfused Retapamulin assessed by Vital Sign measurements
Time Frame: Single day (Pre-dose and at 7th hour Post-dose)
|
Vital Signs include: Systolic and Diastolic Blood Pressure and Pulse Rate.
Pre-dose Vital Signs will be performed in triplicate and all other will be done in duplicate
|
Single day (Pre-dose and at 7th hour Post-dose)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 117151
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 117151Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Infections, Bacterial
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedSkin Infections, BacterialUnited States
-
GlaxoSmithKlineCompletedSkin Infections, BacterialNetherlands, Costa Rica, Germany, Mexico, Canada, India, Poland, South Africa, France, Peru
-
Eastern Virginia Medical SchoolUnited States Department of Defense; Solsys Medical LLCCompletedFurunculosisUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedImpetigoIndia, Mexico, Netherlands, Italy, Peru
-
Ferrer Internacional S.A.Completed
-
Philippine Dermatological SocietySt. Luke's Medical CenterUnknown
-
NovaBay Pharmaceuticals, Inc.Novum Pharmaceutical Research Services; International Dermatology Research,...Completed
-
Paratek Pharmaceuticals IncCompletedInfectious Skin Disease | Bacterial Skin DiseaseUnited States
Clinical Trials on Retapamulin Microdialysis
-
Derm Research, PLLCGlaxoSmithKlineCompletedAtopic Dermatitis | Secondary InfectionUnited States
-
Ferrer Internacional S.A.CompletedEfficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoImpetigoGermany, South Africa
-
Barts & The London NHS TrustImperial College London; Queen Mary University of LondonRecruitingAortic Aneurysm | Aortic Diseases | Aortic Dissection | Aortic ArchUnited Kingdom
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, Germany, Taiwan, Netherlands, Argentina, Chile, Costa Rica, South Africa, Mexico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingGlioblastoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Metastatic Malignant Neoplasm in the Brain | Diffuse GliomaUnited States
-
Centre Hospitalier Universitaire de Saint EtienneUniversity Hospital of Saint-EtienneTerminatedKidney Cancer | Nephrectomy | MicrodialysisFrance
-
Medical University of GrazCompleted
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, South Africa, India, Argentina, Brazil
-
Accunea Ltd.Imperial College Healthcare NHS Trust; Hammersmith Hospitals NHS Trust; Innovate...Withdrawn
-
Imperial College LondonThe Drummond Foundation (RAMC charity)RecruitingCompartment Syndrome of Leg | Limb IschemiaUnited Kingdom